Fentanyl nasal spray for the treatment of cancer pain

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2011-06-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.2011.585637PMID 21609189
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fentanyl Buccal Tablet

  2012cited by this paper
• Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.

  2011cited by this paper
• Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study.

  2010cited by this paper
• Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients.

  2010cited by this paper
• Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers.

  2010cited by this paper
• Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain.

  2010cited by this paper
• A multicenter, placebo‐controlled, double‐blind, multiple‐crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain

  2010cited by this paper
• Fentanyl pectin nasal spray in breakthrough cancer pain.

  2010cited by this paper
• Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188.

  2010cited by this paper
• Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.

  2009cited by this paper
• A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial

  2009cited by this paper
• 29LBA Efficacy, safety and patient acceptability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multicentre, double-blind, double-dummy, multiple-crossover study

  2009cited by this paper
• Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain

  2009cited by this paper
• Fentanyl buccal tablet.

  2008cited by this paper
• Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study.

  2008cited by this paper
• Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?

  2008cited by this paper
• Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology

  2007cited by this paper
• Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.

  2006cited by this paper
• Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.

  2005cited by this paper
• Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics

  2005cited by this paper
• Steady-state kinetics and analgesic effect of oral morphine in cancer patients

  2004cited by this paper
• Cancer breakthrough pain characteristics and responses to treatment at a VA medical center

  2003cited by this paper
• E-TRANS fentanyl. ALZA.

  2002cited by this paper
• Nasal administration of opioids for pain management in adults

  2002cited by this paper
• Morphine and alternative opioids in cancer pain: the EAPC recommendations

  2001cited by this paper
• Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)

  2001cited by this paper
• An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study.

  2000cited by this paper
• A review of the use of fentanyl analgesia in the management of acute pain in adults.

  1999cited by this paper
• Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.

  1999cited by this paper
• Transdermal fentanyl in the long‐term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region

  1997cited by this paper
• Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain.

  1997cited by this paper
• The nasal route of cerebrospinal fluid drainage in man. A light–microscope study

  1994cited by this paper
• Transdermal Fentanyl for Cancer Pain Repeated Dose Pharmacokinetics

  1993cited by this paper
• Pharmakokinetische Studie zur intranasalen Gabe von Fentanyl

  1993cited by this paper
• Doctor, I want to die. Will you help me?

  1993cited by this paper
• [Pharmacokinetics of intranasal Fentanyl.].

  1993cited by this paper
• Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life.

  1990cited by this paper
• Breakthrough pain: definition, prevalence and characteristics

  1990cited by this paper
• Clinical Pharmacokinetics of Fentanyl and its Newer Derivatives

  1983cited by this paper
• Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.

  1982cited by this paper

• Safety profile of fentanyl with different routes of administration: a disproportionality analysis using the EudraVigilance database.

  2026cites this paper
• A deadly trend in fentanyl fatalities (England, 1998-2017).

  2020cites this paper
• Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats.

  2020cites this paper
• Une méta-analyse en réseau de l’efficacité des analgésiques opioïdes dans la prise en charge des épisodes d’accès douloureux paroxystiques d’origine cancéreuse

  2015cites this paper
• Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain

  2015cites this paper
• The Olfactory System as a Route of Delivery for Agents to the Brain and Circulation

  2015cites this paper
• Manejo de opioides para el dolor basal e irruptivo oncológico

  2015cites this paper
• A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.

  2014cites this paper
• Clonidine in pediatric anesthesia : aspects on population pharmacokinetics, nasal administration and safety

  2014cites this paper
• Drug Class Review

  2014cites this paper
• Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

  2014cites this paper
• Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain

  2013cites this paper
• Optimal management of breakthrough cancer pain (BCP)

  2013cites this paper
• ‘Old' and ‘new' drugs for the treatment of cancer pain

  2013influential citation
• Medications for Cancer Breakthrough Pain

  2013cites this paper
• Intranasal Fentanyl for Breakthrough Pain Control

  2012cites this paper
• Perioperative management of the child on long‐term opioids

  2012cites this paper
• Onset time for pharmacologic premedication with clonidine as a nasal aerosol: a double‐blind, placebo‐controlled, randomized trial

  2012cites this paper
• The role of patient‐controlled analgesia in the management of chronic pain

  2011cites this paper
• Fentanyl nasal spray (Lazanda) for pain.

  2011cites this paper
• Fentanyl et accs douloureux paroxystiques chez les patients souffrant de cancer

  2011cites this paper